Brentuximab as a Treatment for CD30+Mycosis Fungoides and Sézary Syndrome-Reference-Cited by-同舟云学术

Brentuximab as a Treatment for CD30+Mycosis Fungoides and Sézary Syndrome

Published:2015-01-01 Issue:1 Volume:151 Page:73
ISSN:2168-6068
Container-title:JAMA Dermatology
language:en
Short-container-title:JAMA Dermatol

Author:

Mehra Tarun¹,Ikenberg Kristian²,Moos Rudolf Maria¹,Benz Rudolf³,Nair Gayathri⁴,Schanz Urs⁴,Haralambieva Eugenia²,Hoetzenecker Wolfram⁵,Dummer Reinhard⁵,French Lars Einar⁵,Guenova Emmanuella⁵,Cozzio Antonio⁵

Affiliation:

1. Office of the Medical Directorate, University Hospital of Zürich, Zürich, Switzerland

2. Department of Pathology, University Hospital of Zürich, Zürich, Switzerland

3. Department of Hematology, Kantonsspital Münsterlingen, Münsterlingen, Switzerland

4. Division of Hematology, University Hospital of Zürich, Zürich, Switzerland

5. Department of Dermatology, University Hospital of Zürich, Zürich, Switzerland

Publisher

American Medical Association (AMA)

Subject

Dermatology

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancements in the treatment of mycosis fungoides and Sézary syndrome: monoclonal antibodies, immunotherapies, and Janus kinase inhibitors;Frontiers in Immunology;2023-11-03

2. Bullous mycosis fungoides with large cell transformation: a fatal outcome following brentuximab treatment;European Journal of Dermatology;2023-10

3. Improved overall survival over time in advanced stage mycosis fungoides: a cross-sectional study;Leukemia & Lymphoma;2022-06-24

4. S2k‐Guidelines – Cutaneous lymphomas (ICD10 C82 ‐ C86): Update 2021;JDDG: Journal der Deutschen Dermatologischen Gesellschaft;2022-04

5. S2k‐Leitlinie – Kutane Lymphome (ICD10 C82–C86): Update 2021;JDDG: Journal der Deutschen Dermatologischen Gesellschaft;2022-04